The Peptide NewsroomPeptide research, industry and supply-chain headlines

Engineered ICOSL Peptide Cuts Proteinuria in Mice, But No Human Trials Yet

Topic card: safety

Researchers have engineered a 19-amino-acid peptide derived from inducible co-stimulator ligand that selectively inhibits activated alpha-v-beta-3 integrin on kidney podocytes, reducing protein in the urine across several animal models of acute and chronic kidney injury.

The work was done entirely in cultured cells and rodents, and the authors describe it as proof of concept with dose-response, administration routes and larger cohorts all still to be established. The target is worth explaining: podocytes are the cells that anchor the kidney's filtration barrier, and overactivated alpha-v-beta-3 integrin is a recognized hallmark of renal inflammation in conditions including focal segmental glomerulosclerosis and diabetic nephropathy. No approved drug directly inhibits that receptor in kidney tissue.

Why previous integrin drugs failed

This is not a new idea, which is most of what makes the paper interesting. Monoclonal antibodies against integrins carry a risk of neutralizing immune responses over long-term dosing, and small-molecule inhibitors have struggled with off-target binding.

The cautionary example is cilengitide, a cyclic pentapeptide that flipped from antagonist at high concentrations to integrin agonist at lower ones during clinical trials. Those paradoxical effects contributed to failures in oncology and stalled translation in nephrology entirely.

The design trick

ICOSL is normally an immune co-stimulatory molecule, but the team isolated its integrin-binding RGD motif from the surface that engages the ICOS receptor, excluding the key contact residues that drive T-cell activation. The resulting peptide, hICOSL-19, bound human alpha-v-beta-3 integrin with a dissociation constant of 25.4 nanomolar and mouse integrin at 44.9 nanomolar, while a scrambled control peptide showed no measurable interaction.

Unmodified, it cleared fast: a terminal plasma half-life of 14.96 minutes. Adding twelve polyethylene glycol units extended that more than three-fold, to 46.74 minutes, without losing target affinity.

Key results

In BTBR ob/ob mice, a genetic model of obesity and advanced diabetic nephropathy, daily intravenous dosing at 500 micrograms per kilogram for six weeks significantly reduced the urinary albumin-to-creatinine ratio against animals given an inactive control peptide, with no change in body weight. Electron microscopy showed less podocyte foot process effacement and normalization of basement membrane thickening.

Limitations

Only one dose was tested, and the diabetic cohort was small. Human trials have not begun, and the authors note that nephrology runs on combination regimens, so interactions with RAAS inhibitors, SGLT2 inhibitors and GLP-1 receptor agonists remain unexamined.

Bottom line

A clean safety signal and consistent results across mechanical, metabolic and immunological injury models is a stronger preclinical package than most peptide stories arrive with. It is still rodent data on a target that has defeated three previous drug classes.

Source: RSS.app — Peptides bundle. Read the original.

Filed under: safety, glp-1, recovery

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

Karnataka Regulators Cancel a Bengaluru Peptide Party as India's Longevity Market Accelerates

Karnataka's drug regulator canceled a Bengaluru "Peptide Party" on August 29 and questioned the organizers about ingredients, legality and health claims. The Indian Express reports the shutdown against a biohacking market Grand View Research valued at $1.21 billion in 2025.

What the Research Actually Says About Semaglutide, From Weight Loss to Memory

Semaglutide has large human trials behind its weight and metabolic outcomes, but the newer questions about energy expenditure, muscle preservation and cognition are far less settled. A digest of what researchers have actually reported, and where the evidence stops.

Kemin Pitches Positive Aging, GLP-1 Support and Gut Health as Its 2027 Trends

Kemin's Filipa Quintela told Nutritional Outlook at SupplySide Global that positive aging, GLP-1 support through Slendesta, and gut health via the Gutopia platform will shape the supplier's 2027 development. She also put American lutein intake at around 2 mg a day against an optimal 10 mg.